Company intelligence / Profile preview
Vactech
Tampere, Western Finland, Finlandvactech.fi ↗
- Ownership
- Private
- Employees
- ~8
- Development stage
- Other
01
Overview
Vactech has published proof-of-concept preclinical data for its Coxsackievirus B vaccine prototype and is advancing programs in prevention and diagnosis of type 1 diabetes and celiac disease
- Therapeutic areas
- Infectious DiseasesEndocrinologyGastroenterology
- Modalities
- VaccineDiagnostic
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Provention Bio (vaccine development and licensing partnership)
Beyond the preview
Go deeper on Vactech.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Vactech.